

Clinical Policy: Selexipag (Uptravi)

Reference Number: CP.PHAR.196

Effective Date: 03.16

Last Review Date: 02.18

Line of Business: Commercial, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Selexipag (Uptravi[®]) is a prostacyclin receptor agonist.

FDA Approved Indication(s)

Uptravi is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1) to delay disease progression and reduce the risk of hospitalization for PAH.

Effectiveness was established in a long-term study in PAH patients with WHO Functional Class II-III symptoms. Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), and PAH associated with congenital heart disease with repaired shunts (10%).

Policy/Criteria

Provider must submit documentation (including such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Uptravi is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Pulmonary Hypertension (must meet all):

1. Diagnosis of PAH;
2. Prescribed by or in consultation with a cardiologist or pulmonologist;
3. Failure of a trial of a calcium channel blocker (*see Appendix B*), unless member meets one of the following (a or b):
 - a. Inadequate response or contraindication to acute vasodilator testing;
 - b. Contraindication or clinically significant adverse effects to a calcium channel blocker are experienced;
4. Dose does not exceed 1600 mcg twice daily.

Approval duration:

Medicaid - 6 months

Commercial – Length of benefit

B. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Pulmonary Hypertension (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed 1600 mcg twice daily.

Approval duration:

Medicaid - 12 months

Commercial – Length of benefit

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

Approval duration: Duration of request or 6 months (whichever is less); or

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FC: functional class

FDA: Food and Drug Administration

NYHA: New York Heart Association

PAH: pulmonary arterial hypertension

PH: pulmonary hypertension

WHO: World Health Organization

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

| Drug Name | Dosing Regimen | Dose Limit/ Maximum Dose |
|---|--|-----------------------------|
| nifedipine (Adalat [®] CC, Afeditab [®] CR, Procardia [®] , Procardia XL [®]) | 60 mg PO QD; may increase to 120 to 240 mg/day | 240 mg/day |
| diltiazem (Dilacor XR [®] , Dilt-XR [®] , Cardizem [®] CD, Cartia XT [®] , Tiazac [®] , Taztia XT [®] , Cardizem [®] LA, Matzim [®] LA) | 720 to 960 mg PO QD | 960 mg/day |

CLINICAL POLICY
Selexipag

| Drug Name | Dosing Regimen | Dose Limit/ Maximum Dose |
|-----------------------|-------------------|-----------------------------|
| amlodipine (Norvasc®) | 20 to 30 mg PO QD | 30 mg/day |

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Pulmonary Hypertension: WHO Classification

- Group 1: PAH (pulmonary arterial hypertension)
- Group 2: PH due to left heart disease
- Group 3: PH due to lung disease and/or hypoxemia
- Group 4: CTEPH (chronic thromboembolic pulmonary hypertension)
- Group 5: PH due to unclear multifactorial mechanisms

Appendix D: Pulmonary Hypertension: WHO/NYHA Functional Classes (FC)

| Treatment Approach* | FC | Status at Rest | Tolerance of Physical Activity (PA) | PA Limitations | Heart Failure |
|--|-----|---|--|---|------------------------------|
| Monitoring for progression of PH and treatment of co-existing conditions | I | Comfortable at rest | No limitation | Ordinary PA does not cause undue dyspnea or fatigue, chest pain, or near syncope. | |
| Advanced treatment of PH with PH-targeted therapy - see Appendix E** | II | Comfortable at rest | Slight limitation | Ordinary PA causes undue dyspnea or fatigue, chest pain, or near syncope. | |
| | III | Comfortable at rest | Marked limitation | Less than ordinary PA causes undue dyspnea or fatigue, chest pain, or near syncope. | |
| | IV | Dyspnea or fatigue may be present at rest | Inability to carry out any PA without symptoms | Discomfort is increased by any PA. | Signs of right heart failure |

*PH supportive measures may include diuretics, oxygen therapy, anticoagulation, digoxin, exercise, pneumococcal vaccination. **Advanced treatment options also include calcium channel blockers.

Appendix E: Pulmonary Hypertension: Targeted Therapies

| Mechanism of Action | Drug Class | Drug Subclass | Drug | Brand/Generic Formulations |
|------------------------|-------------------------------|---------------|--------------|---|
| Reduction of pulmonary | Prostacyclin* pathway agonist | Prostacyclin | Epoprostenol | Velettri (IV) Flolan (IV) Flolan generic (IV) |

| Mechanism of Action | Drug Class | Drug Subclass | Drug | Brand/Generic Formulations |
|--|---|--|--------------|--|
| arterial pressure through vasodilation | <i>*Member of the prostanoid class of fatty acid derivatives.</i> | Synthetic prostacyclin analog | Treprostinil | Orenitram (oral tablet) Remodulin (IV) Tyvaso (inhalation) |
| | | | Iloprost | Ventavis (inhalation) |
| | | Non-prostanoid prostacyclin receptor (IP receptor) agonist | Selexipag | Uptravi (oral tablet) |
| | Endothelin receptor antagonist (ETRA) | Selective receptor antagonist | Ambrisentan | Letairis (oral tablet) |
| | | Nonselective dual action receptor antagonist | Bosentan | Tracleer (oral tablet) |
| | | | Macitentan | Opsumit (oral tablet) |
| | Nitric oxide-cyclic guanosine monophosphate enhancer | Phosphodiesterase type 5 (PDE5) inhibitor | Sildenafil | Revatio (IV, oral tablet, oral suspension) |
| | | | Tadalafil | Adcirca (oral tablet) |
| | | Guanylate cyclase stimulant (sGC) | Riociguat | Adempas (oral tablet) |

V. Dosage and Administration

| Indication | Dosing Regimen | Maximum Dose |
|---------------------------------|--|--------------|
| Pulmonary arterial hypertension | 200 mcg PO BID, increased at weekly intervals to highest tolerated dose up to 1600 mcg BID | 3200 mcg/day |

VI. Product Availability

Tablets: 200 mcg, 400 mcg, 600 mg, 800 mg, 1000 mcg, 1200 mcg, 1400 mcg, 1600 mcg

VII. References

1. Uptravi Prescribing Information. South San Francisco, CA: Actelion Pharmaceuticals US, Inc.; September 2017. Available at <https://www.uptravi.com/assets/pdf/UPTRAVI-full-prescribing-information.pdf>. Accessed November 21, 2017.
2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart

CLINICAL POLICY
Selexipag

- Association - developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009; 53(17): 1573-1619.
3. Taichman D, Ornelas J, Chung L, et. al. CHEST guideline and expert panel report: Pharmacologic therapy for pulmonary arterial hypertension in adults. Chest. 2014; 146 (2): 449-475.
 4. Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: Guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015 Nov 24; 132(21): 2037-99.
 5. Kim NH, Delcroix M, Jenkins DP, et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013; 62(25): Suppl D92-99.
 6. Galiè N, Humbert M, Vachiary JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of Pulmonary Hypertension. European Heart Journal. Doi:10.1093/eurheartj/ehv317.

| Reviews, Revisions, and Approvals | Date | P&T Approval Date |
|---|----------|-------------------|
| <p>Policy split from CP.PHAR.33.PAH and converted to new template.</p> <p>Criteria: added specialist requirement; removed echocardiogram as an option for confirming a PH diagnosis; removed hard stop after 3 months of therapy.</p> <p>Appendices removed: 1) examples of calcium channel blocker contraindications; 2) nitrate therapy examples; 3) PAH definition.</p> | 02.16 | 03.16 |
| <p>Age restriction removed. FC II added to the prostanoid class of PH drugs.</p> <p>Safety criteria were removed unless they 1) represent contraindications or black box warnings not covered by a REMS program, and 2) provide specific lab/imaging parameters that must be met prior to initiation of therapy.</p> <p>An efficacy statement is added to the continuation criteria.</p> <p>Initial and continuation durations increased to 6 and 12 months respectively.</p> <p>Appendices covering PH groups, functional class and therapies reorganized.</p> | 02.17 | 03.17 |
| <p>1Q18 annual review:</p> <ul style="list-style-type: none"> - Policies combined for commercial, HIM and Medicaid - No significant changes from previous corporate approved policy. - Medicaid: removed WHO/NYHA classifications from initial criteria since specialist is involved in care. - References reviewed and updated. | 11.20.17 | 02.18 |

CLINICAL POLICY

Selexipag

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members

CLINICAL POLICY
Selexipag

and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.